Work

Supplementary Figures 1 through 10 and Supplementary Tables 1 through 4 from Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

Year: 2023
Type: supplementary-materials
Abstract: Figure S1 Schema of the Neoadjuvant and Adjuvant Study of Panc GVAX. Figure S2 Pre- and post-vaccination mesothelin peptide-specific T cell levels in responders versus nonresponders. Figure S3 Intratumoral tertiary lymphoid aggregate in PDACs from patients treated with GVAX and lymphocyte cluster in PDACs from patients not treated with GVAX. Figure S4 The development of post-vaccination intratumoral lymphoid aggregates is associated with survival. Figure S5 Relatively more Granzyme B expressing cells observed outside of the lymphoid aggregates. Figure S6 Microdissection of Lymphoid Aggregates for Microarray Analysis. Figure S7 Microarray analysis of lymphoid aggregates revealed gene signatures in four pathways involved in regulating immune cell trafficking and function. Figure S8 Decreased Treg and increased TH17 pathway gene expression signatures are associated with improved post-vaccination responses. Figure S9 Downregulation of Treg pathway gene expression in TIL following treatment with PDAC GVAX is associated with longer survival. Figure S10 IL17A-producing T cells are present in low levels in TIL from PDAC GVAX treated patients. Figure S11 Treatment with low dose Cy increases post-vaccination densities of intratumoral lymphoid aggregates and reduces Treg levels in the PDAC TME. Figure S12 T cell infiltration in PDACs with low versus high CD8/Foxp3 ratio. Table S1 Immunohistochemistry protocols. Table S2 Quantitative real-time RT-PCR primers. Table S3 Scores of TH1, TH2, Treg, and TH17 pathway gene expression in PDAC TIL analyzed by quantitative real-time RT-PCR. Table S4 Numbers of TIL specimens with detectable expression of immune related genes.
Language: English
Subfield: Immunology
Open Access status: gold
OpenAlex ID: W4362629079
Cites:
Cited by:
Related to: 10